Figure 3. S. typhimuium A1-R-decoyed tumors became sensitive to chemotherapy.

FUCCI-expressing MKN45 cells (5 × 10⁶ cells/mouse) were injected subcutaneously into the left flank of nude mouse. When the tumors reached approximately 8 mm in diameter (tumor volume, 300 mm³), mice were administered iv S. typhimuium A1-R alone, or with cisplatinum (4 mg/kg ip) or paclitaxel (5 mg/kg ip) for five cycles every 3 days. (A) Representative images of cross-sections of FUCCI-expressing MKN45 subcutaneous tumors, untreated control, S. typhimuium A1-R-treated, cisplatinum-treated, paclitaxel-treated, or treated with the combination of S. typhimuium A1-R and either cisplainum or paclitaxel. (B) Growth curves of tumors derived from FUCCI-expressing MKN45 cells after treatment with chemotherapy, S. typhimuium A1-R or the combination of S. typhimuium A1-R and chemotherapy. The difference between control and cisplatinum-treated, p<0.01; the difference between control and paclitaxel-treated, p<0.05; the difference between control and S. typhimuium A1-R, p<0.05; the difference between control and the combination of S. typhimuium A1-R and cisplatinum, p<0.01; the difference between control and the combination of S. typhimuium A1-R and paclitaxel, p<0.01. (C) Histogram shows cell cycle phase of FUCCI-expressing MKN45 subcutaneous tumors, untreated control, S. typhimuium A1-R-treated, cisplatinum-treated, paclitaxel-treated, or the combination of S. typhimuium A1-R and either cisplatinum or paclitaxel. Scale bars; 500 µm. Reproduced with permission from [14].